COMMUNIQUÉS West-GlobeNewswire

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
09/01/2026
Company to present Tuesday, January 13 th at 10:00 a.m. PT / 1:00 p.m. ET GAITHERSBURG, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix [...]
Flare Therapeutics Appoints Stephen L. Eck, M.D., Ph.D., as Chief Medical Officer
09/01/2026
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity
09/01/2026
PLANEGG, Germany and MUNICH, Jan. 09, 2026 (GLOBE NEWSWIRE) -- A new study published in Pharmaceutics ( https://doi.org/10.3390/pharmaceutics18010050 ) shows that LEON’s FR-JET ® modular mixer addresses key [...]
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
09/01/2026
-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product [...]
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
09/01/2026
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending [...]
Tecan to present at upcoming Investor Conferences
09/01/2026
Männedorf, Switzerland, January 9, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences in the upcoming week: 44 th Annual J.P. Morgan [...]
Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine
09/01/2026
WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the [...]
uniQure Announces Type A Meeting Scheduled with FDA
09/01/2026
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a [...]
ACTG Launches IPACE-HIV to Study Frailty Intervention
09/01/2026
CHAPEL HILL, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IPACE-HIV study (Improving Physical Ability [...]
Sienna Announces Fourth Quarter 2025 Results Release Date and Conference Call
09/01/2026
MARKHAM, Ontario, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2025 fourth quarter results after market close on Thursday, [...]
Remedy’s Nutrition® Unveils Hair Tissue Mineral Analysis: A Revolutionary Personalized Approach to Nutritional Wellness
09/01/2026
KEY LARGO, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Remedy's Nutrition® , a pioneering natural health company established in 1972, today announced the launch of its cutting-edge diagnostic service: Hair Tissue Mineral [...]
Dogecoin Cash, Inc. Becomes Among the First U.S. Public Companies to Complete a FINRA‑Notified Blockchain‑Linked Security Distribution
09/01/2026
FINRA Daily List Confirms “ Dividend Payable in Another Security” for DOGP MESQUITE, NV, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV January 9, 2026 — Dogecoin Cash, Inc. (OTC: DOGP) today announced that the [...]
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
09/01/2026
Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history. Q4 2025 revenue [...]
RadNet, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026
09/01/2026
LOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated [...]
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”
09/01/2026
New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation BOTHELL, Wash., Jan. 09, 2026 (GLOBE [...]
Avance Clinical to Showcase New Early Phase Center of Excellence at Biotech Showcase 2026
09/01/2026
ADELAIDE, Australia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced today that [...]
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
09/01/2026
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
09/01/2026
Immunocore announces 2026 strategic priorities at 44 th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global [...]
Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes
09/01/2026
PRESS RELEASE Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes First conceptual model demonstrating the impact of BK polyomavirus on the health-related [...]

Pages